Meningioma Pipeline Review: H1 2018 - Covering Therapeutics Under Development by Companies/Universities/Institutes - ResearchAndMarkets.com

DUBLIN--()--The "Meningioma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This latest pipeline guide provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 4 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 2 molecules, respectively.

Companies Mentioned

  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Co
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Merck & Co Inc
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc

Key Topics Covered

  1. Introduction
  2. Meningioma - Overview
  3. Meningioma - Therapeutics Development
  4. Meningioma - Therapeutics Assessment
  5. Meningioma - Companies Involved in Therapeutics Development
  6. Meningioma - Drug Profiles
  7. Meningioma - Dormant Projects
  8. Meningioma - Discontinued Products
  9. Meningioma - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/87ksls/meningioma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs